Bioinformatics analysis of the target gene of fibroblast growth factor receptor 3 in bladder cancer and associated molecular mechanisms
- Authors:
- Published online on: May 19, 2015 https://doi.org/10.3892/ol.2015.3231
- Pages: 543-549
Abstract
Introduction
Bladder cancer (BC) is estimated to be among the top five most common types of cancer in western countries and ranks number 13 in terms of cancer-associated mortality worldwide (1,2). Histologically, BC may be classified based on the depth of invasion: pTa, papillary; pT1, lamina propria invasion; pT2, muscle invasive; pT3, invasion to peri-vesical fat; and pT4, locally advanced (3,4). BC results from long-term exposure to contaminants or other environmental factors involving gene mutations and progressive cellular damage. Parkin et al (5) demonstrated that the incidence of BC is almost four times higher in men than in women and inducing factors include tobacco smoke, prolonged exposure to chemical substances and race (6,7).
Genetic mutations in gene expression may lead to the malignant transformation of bladder cells. High-throughput DNA microarray analyses have identified multiple DNA mutations and alterations in the genesis of BC; these include genes encoding for B cell lymphoma-2, p53, H-Ras and fibroblast growth factor receptor 3 (FGFR3) (8,9). FGFR3 is a tyrosine kinase receptor that regulates fundamental developmental pathways and triggers a range of cellular processes, including proliferation, differentiation, migration and apoptosis (10). The FGFR3 gene is located on chromosome region 4p16.3 (11) and it is made up of 9 exons and 18 introns (12). The structure of FGFR3 is composed of an extracellular domain consisting of two or three immunoglobulin-like domains, a hydrophobic transmembrane domain and an intracellular tyrosine kinase domain (13). Upon ligand binding, FGFR3 forms dimers and activates the intracellular kinase domain, resulting in autophosphorylation of this domain. The phosphorylated residues are the binding targets of the adaptor proteins and their binding results in the activation of several signal transduction pathways, including the Ras mitogen-activated protein kinase (MAPK) signaling pathway and phosphoinositide 3-kinase (PI3K) Akt mammalian target of rapamycin (mTOR) pathway (14).
There are two mechanisms to explain the abnormal activation of FGFR3: Overexpression or activating mutations. FGFR3 mutations have been identified in multiple dwarfisms (15), such as hypochondroplasia, and in multiple types of cancer, including prostate cancer (16), cervical cancer (17) and BC. FGFR3 mutations were reported in BC for the first time by Cappellen et al (18). There is evidence to suggest that codons 248, 249 and 375 are the major mutation hot spots in BC (19); in addition, activating mutations of FGFR3 have been revealed primarily in pTa (60–70%) and in pT1-4 (16–20%) (19). Overexpression of FGFR3 has been frequently identified in BC; furthermore, Jebar et al (20) demonstrated that the expression of FGFR3 was higher in low stage BC. Du et al (21) identified a gene pathway linking FGFR3 with sterol and lipid metabolism through transcriptional profiling of BC cells subjected to short hairpin (sh)RNA knockdown of FGFR3 (21). FGFR3 has been demonstrated to be a promising therapeutic target for BC (22,23). However, the molecular mechanisms of FGFR3 activation, via overexpression or activating mutation, in BC remain to be elucidated.
The present study aimed to analyze microarray data in order to investigate the changes in gene expression profiles that occur following loss of FGFR3; in addition, the current study aimed to explore the target genes and molecular mechanisms of FGFR3 The genes that were differentially expressed in FGFR3-deleted cell lines as compared with the control cell lines were considered to be potential transcriptional targets of over-expressed FGFR3 in bladder cancer. Furthermore, a protein-protein interaction (PPI) network was constructed and the disturbed biological pathways were identified following FGFR3 knockdown in order to explore the pathogenesis and occurrence of BC associated with FGFR3.
Materials and methods
Messenger RNA expression profile data of BC
The transcription profile dataset of BC was obtained from National Center of Biotechnology Information Gene Expression Omnibus database (http://www.ncbi.nlm.nih.gov/geo/). The accession number was GSE41035 and the dataset consisted of a total of 24 mRNA samples, including 18 experimental samples collected from RT112 cell lines, with FGFR3 shRNA 2–4, FGFR3 shRNA 4-1 or FGFR3 shRNA 6–16, as well as 6 control enhanced green fluorescent protein (EGFP) shRNA samples. The platform used was GPL570 Affymetrix Human Genome U133 Plus 2.0 array (Affymetrix, Inc., Santa Clara, CA, USA). The original CEL files and the annotations file were downloaded based on this platform.
Identification of differentially expressed genes (DEGs)
Probe-level data in the CEL files were first converted into expression measures. For each sample, the expression values of all probes for a given gene were reduced to a single value by taking the average expression value. Subsequently, missing data was imputed and quartile data normalization was performed by robust multichip averaging using Affy package in R software (version 3.1; http://www.bioconductor.org/packages/release/bioc/html/affy.html) (24). The Limma package version 3.24.2 (http://www.bioconductor.org/packages/release/bioc/html/limma.html) (25) in R language with multiple testing correction was then used according to the Benjamini & Hochberg method (26) in order to identify DEGs between BC samples and normal controls. P<0.05 and |log(fold change; FC)|>1 were defined as the thresholds.
Gene ontology (GO) enrichment analysis
In order to investigate DEGs at the molecular and functional level, the online biological tool, Database for Annotation, Visualization and Integrated Discovery (DAVID) version 6.7 (http://david.abcc.Ncifcrf.gov/), was used for GO term enrichment and genes were clustered according to GO. GO is a collection of controlled vocabularies, which include molecular function, cellular component and biological process, to describe the biology of a gene product in any organism. P<0.05 was selected as the cut-off criterion during the analysis.
Pathway enrichment analysis
The theoretical principle for enrichment analysis is that associated functional genes are more likely to be selected in the abnormal biological process by the high-through screening technologies (27). Based on the selected genes, researchers are able to correctly identify the biological processes involved. In order to identify the enriched pathways of DEGs, DAVID was used with P<0.05 as the threshold. The pathways used as DAVID input for cluster analysis were from Kyoto Encyclopedia of Genes and Genomes (KEGG; http://www.genome.jp/kegg/) and BIOCARTA (http://www.biocarta.com/).
PPI network construction
PPIs are crucial for all biological processes. In the present study, the PPI network was constructed based on the Protein Interaction Network Analysis platform (PINA2) database (http://cbg.garvan.unsw.edu.au/pina/). PINA2 (28) is a database containing known and predicted associations of protein interaction. The interactions include direct (physical) and indirect (functional) associations. Of note, the protein names in the Universal Protein Resource database (http://www.ebi.ac.uk/uniprot/remotingAPI/), which correspond to the DEGs, were submitted to construct the PPI network. Here Cytoscape software (version 3.2.1; http://cytoscape.org/) (29) was used to visualize the PPI network to further observe the associations between genes.
Analysis of co-expressed genes
DEGs only explain a limited number of mechanisms of FGFR3-shRNA in BC. However, analysis of differential co-expression genes may reveal two or several similar genes with similar expression patterns across a set of samples. Co-expression genes were hypothesized to have a functional association, such as physical interaction between the encoded proteins (30,31). In order to further explore the pathogenesis of BC in the present study, the differential coexpression enrichment (DCe) function in DGCL package (32) version 2.1.2 (http://cran.r-project.org/web/packages/DCGL/index.html) in R language was used and the parameters in the function were set to default values. P<0.05 and the maximum absolute correlation coefficient >1.5 were set as thresholds.
Results
Identification of DEGs
The Limma package was used to analyze the transcription profile data between the experimental and control samples. P<0.05 and |logFC|>1 were used as the significant thresholds for DEGs. Based on these criteria, a total of 196 DEGs were identified, among which 101 were downregulated and 95 were upregulated.
GO analysis
Functional classification was performed using the online biological tool DAVID, with a threshold of P<0.05. Table I demonstrates the top ten significantly enriched GO terms when these DEGs were classified according to biological process. This analysis revealed that the most enriched functions detected in FGFR3 knockdown samples compared with control samples were the biosynthesis of sterol (P=8.87×10−8)and metabolism of sterol (P=1.58×10−7) or steroid (P=3.52×10−7). In addition, oxidation reduction, extracellular region part and identical protein process were also demonstrated to be enriched.
Analysis of the biological pathways of DEGs
The gene transcription profile was significantly altered in experimental samples compared with control samples. These DEGs were selected for KEGG and BIOCATRA pathway enrichment analysis. As shown in Table II, according to the threshold of P<0.05, six biological pathways were significantly enriched. Consistent with the results of the GO enrichment analysis, these pathways were primarily associated with biosynthesis and metabolism, including steroid biosynthesis (P=4.80×10−5) and arachidonic acid metabolism (P=0.03285).
PPI network construction
DEGs were mapped to a PINA2 database and a PPI network was constructed. The PPI network identified 1,865 genes, with 2,482 interactions between them (Fig. 1). Genes that had more interactions with other genes may have a critical role in BC. Table III demonstrates the DEGs with the ten highest degrees of gene interactions identified in these samples. The gene SETX was reported to have the highest degree (degree, 159), which indicated that it may have an important role in FGFR3-regulated BC.
Analysis of co-expressed genes
Co-expressed genes were identified using DCe function in R language; a gene co-expression network was then constructed and visualized using Cytoscape. The network involved 1,935 co-expression associations between 140 differentially co-expressed genes and 798 non-differentially co-expressed genes (Fig. 2). Table IV lists the differentially co-expressed genes with the ten highest degrees of gene interactions, among which CCNB1 was the top hub gene with the highest degree (degree, 39).
Table IV.Ten highest degrees of interaction and the corresponding differentially co-expressed genes. |
Discussion
BC is the fourth most common type of solid cancer in men and the seventh most common in women, worldwide. Although mutations and overexpression of FGFR3 have been associated with BC, the biological mechanisms underlying its pathogenesis remain to be fully elucidated. The present study aimed to analyze DEGs based on the transcription profile data of experimental FGFR3 knockdown samples and control EGFP shRNA samples. A total of 196 genes were identified to be differentially expressed in FGFR3 knockdown bladder cancer cell lines in comparison with control cell lines. GO and pathway enrichment analysis were conducted; in addition, a PPI network of DEGs and a differential co-expression network were constructed.
In the present study, the results of the GO analysis as well as the KEGG and BIOCATRA pathway enrichment analysis revealed that the primary biological process in which these DEGs were involved was sterol biosynthesis and metabolism. These results were consistent with those of a previous study, which demonstrated that FGFR3 may affect BC through the biosynthesis of sterol and lipids (21). Activation of FGFR3 was reported to promote the accumulation of mature sterol-regulatory element binding protein (SREBP)-1 through the PI3K-mTOR complex 1 pathway (21). SREBPs belong to the basic helix-loop-helix-leucine zipper family of transcription factors, which include SREBP-1a, SREBP-1C and SREBP-2. These transcription factors have been reported to be regulators of the activation or expression of enzymes in lipid and cholesterol homeostasis (33). Such enzymes include lanosterol-14α-demethylase, squalene epoxidase monooxygenase, sterol-Δ7-reductase, farnesyl-diphosphate farnesyl transferase 1 and sterol-C4-methyl oxidase, encoded for by CYP51A1, SQLE, DHCR7, FDFT1 and SC4MOL, respectively, which were genes identified in the present study to be involved in the top biological process affected by FGFR3 knockdown in BC, steroid biosynthesis. When sterol concentrations are low, SREBPs bind with SREBP cleavage-activating protein and mature SREBPs activate the biosynthesis of sterol (34). Wu et al (35) and Degener et al (36) revealed an association between the metabolism of steroid or bile acid and bladder cancer. Therefore, it was hypothesized that FGFR3 may regulate the corresponding target genes, which in turn affects the metabolism and biosynthesis of steroid substances and subsequently affects BC.
The genes with the ten highest degrees of interaction in the PPI network constructed in the present study were SETX, CFD, HIST2H2BE, NME2, SERPINB2, UBC, CKS, DHRS2, TRIP6 and MCM5. NME2, also known as NM23-H2, encodes nucleoside diphosphate kinase (NDPK)-B, which catalyzes the transposition of γ-phosphate between nucleosides (37). In addition, NME2 is known to be a motility and metastasis suppressor (38), which may inhibit cancer, as cells must survive and proliferate to become overt metastases. NME1, also known as NM23-H2, is a paralog of NME2, with 88% amino acid identity, and was first discovered to be a metastasis suppressor by Steeg et al (39) in 1988. Yong et al (40) studied the differential expression of NM23-H1 in BC and normal bladder cases using the immunohistochemical technique streptavidin-peroxidase procedure and demonstrated that the positive expression rates of NM23-H1 were 62.3 and 100.0% in BC and normal bladder, respectively. With disease progression, the positive expression rate decreased indicating its important role in BC (40). NM23 phosphorylates kinase suppressor of Ras and prevents downstream activation of the MAPK pathway (41). Therefore, FGFR3 expression may lead to the activation of the MAPK pathway. Furthermore, numerous studies have provided evidence to suggest that the NME2 gene may be associated with cancer (42,43).
Co-expression genes were hypothesized to have functional associations, such as physical interactions, between the encoded proteins. In the present study, the gene co-expression network containing 168 differentially co-expressed genes and 1,935 associations were built. The genes with the highest degrees of interaction were CCNB1, MCM3, TMEM97, MCM5, H2AFZ, PPIL1, UBE2T, MCM2, CTSF and ZIC2. CCNB1, encoding cyclin B1, was reported to contribute to the regulation of G2-M-phase transition, which is essential for DNA synthesis and cell proliferation (44). Dysregulated expression of CCNB1 may therefore result in uncontrolled growth and malignant transformation (45). Of note, CCNB1 is one of the 11 genes to predict outcome in several types of cancer, including BC (46). Yuan et al (47) reported that the specific downregulation of CCNB1 may lead to tumor regression through preventing the progression of cells in G2 phase and triggering cell death. H2AFZ encodes H2A histone family, member Z, which is a variant of histone H2A and is responsible for the thermosensory response and regulating euchromatin-heterochromatin transition (48). H2AFZ may have a role in high-grade cancer due to its ability to regulate a large numbers of genes (49). Dong et al (50) revealed that H2AFZ was overexpressed in BC and may be applied to the diagnosis of BC.
In conclusion, according to the expression profile data of FGFR3 knockdown in BC, the present study identified 196 DEGs. GO analysis as well as KEGG and BIOCATRA pathway enrichment analysis revealed that the primary biological process in which these DEGs were involved was sterol biosynthesis and metabolism. In addition, PPI networks of DEGs and co-expressed genes were constructed and revealed the information flow of PPIs. This comprehensive expression profile data of BC provided novel insight into the pathogenesis and occurrence of BC associated with FGFR3.
References
Bryan RT: Update on bladder cancer diagnosis and management. Trends in Urology and Men's Health. 4:7–11. 2013. | |
Ploeg M, Aben KK and Kiemeney LA: The present and future burden of urinary bladder cancer in the world. World J Urol. 27:289–293. 2009. View Article : Google Scholar : PubMed/NCBI | |
Billerey C, Chopin D, Aubriot-Lorton MH, et al: Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol. 158:1955–1959. 2001. View Article : Google Scholar : PubMed/NCBI | |
Heney NM: Natural history of superficial bladder cancer. Prognostic features and long-term disease course. Urol Clin North Am. 19:429–433. 1992.PubMed/NCBI | |
Parkin DM: The global burden of urinary bladder cancer. Scand J Urol Nephrol Suppl. 218:12–20. 2008. View Article : Google Scholar : PubMed/NCBI | |
Boffetta P: Tobacco smoking and risk of bladder cancer. Scand J Urol Nephrol Suppl. 218:45–54. 2008. View Article : Google Scholar : PubMed/NCBI | |
Zeegers MP, Tan FE, Dorant E and van Den Brandt PA: The impact of characteristics of cigarette smoking on urinary tract cancer risk: A meta-analysis of epidemiologic studies. Cancer. 89:630–639. 2000. View Article : Google Scholar : PubMed/NCBI | |
Sánchez-Carbayo M and Cordon-Cardó C: Molecular alterations associated with bladder cancer progression. Semin Oncol. 34:75–84. 2007. View Article : Google Scholar : PubMed/NCBI | |
Cordon-Cardo C: Molecular alterations associated with bladder cancer initiation and progression. Scand J Urol Nephrol Suppl. 218:154–165. 2008. View Article : Google Scholar : PubMed/NCBI | |
Ornitz DM, Xu J, Colvin JS, et al: Receptor specificity of the fibroblast growth factor family. J Biol Chem. 271:15292–15297. 1996. View Article : Google Scholar : PubMed/NCBI | |
Thompson LM, Plummer S, Schalling M, et al: A gene encoding a fibroblast growth factor receptor isolated from the Huntington disease gene region of human chromosome 4. Genomics. 11:1133–1142. 1991. View Article : Google Scholar : PubMed/NCBI | |
Perez-Castro AV, Wilson J and Altherr MR: Genomic organization of the human fibroblast growth factor receptor 3 (FGFR3) gene and comparative sequence analysis with the mouse Fgfr3 Gene. Genomics. 41:10–16. 1997. View Article : Google Scholar : PubMed/NCBI | |
Pandith AA, Shah ZA and Siddiqi MA: Oncogenic role of fibroblast growth factor receptor 3 in tumorigenesis of urinary bladder cancer. Urol Oncol. 31:398–406. 2013. View Article : Google Scholar : PubMed/NCBI | |
Turner N and Grose R: Fibroblast growth factor signalling: From development to cancer. Nat Rev Cancer. 10:116–129. 2010. View Article : Google Scholar : PubMed/NCBI | |
Passos-Bueno MR, Wilcox WR, Jabs EW, Sertié AL, Alonso LG and Kitoh H: Clinical spectrum of fibroblast growth factor receptor mutations. Hum Mutat. 14:115–125. 1999. View Article : Google Scholar : PubMed/NCBI | |
Hernández S, de Muga S, Agell L, et al: FGFR3 mutations in prostate cancer: association with low-grade tumors. Mod Pathol. 22:848–856. 2009.PubMed/NCBI | |
Rosty C, Aubriot MH, Cappellen D, et al: Clinical and biological characteristics of cervical neoplasias with FGFR3 mutation. Mol Cancer. 4:152005. View Article : Google Scholar : PubMed/NCBI | |
Cappellen D, De Oliveira C, Ricol D, et al: Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet. 23:18–20. 1999. View Article : Google Scholar : PubMed/NCBI | |
Billerey C, Chopin D, Aubriot-Lorton MH, et al: Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol. 158:1955–1959. 2001. View Article : Google Scholar : PubMed/NCBI | |
Jebar AH, Hurst CD, Tomlinson DC, Johnston C, Taylor CF and Knowles MA: FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene. 24:5218–5225. 2005. View Article : Google Scholar : PubMed/NCBI | |
Du X, Wang QR, Chan E, et al: FGFR3 stimulates stearoyl CoA desaturase 1 activity to promote bladder tumor growth. Cancer Res. 72:5843–5855. 2012. View Article : Google Scholar : PubMed/NCBI | |
Tomlinson DC, Hurst CD and Knowles MA: Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer. Oncogene. 26:5889–5899. 2007. View Article : Google Scholar : PubMed/NCBI | |
Miyake M, Ishii M, Koyama N, et al: 1-tert-butyl-3-[6-(3, 5-dimethoxy-phenyl)-2-(4-diethylamino-butylamino)-pyrido [2, 3-d] pyrimidin-7-yl]-urea (PD173074), a selective tyrosine kinase inhibitor of fibroblast growth factor receptor-3 (FGFR3), inhibits cell proliferation of bladder cancer carrying the FGFR3 gene mutation along with up-regulation of p27 Kip1 and G1 G0 arrest. J Pharmacol Exp Ther. 332:795–802. 2010. View Article : Google Scholar : PubMed/NCBI | |
Irizarry RA, Hobbs B, Collin F, et al: Exploration, normalization and summaries of high density oligonucleotide array probe level data. Biostatistics. 4:249–264. 2003. View Article : Google Scholar : PubMed/NCBI | |
Smyth GK: Limma: linear models for microarray dataBioinformatics and Computational Biology Solutions Using R and Bioconductor. Gentleman R, Carey V, Huber W, Irizarry RA and Dudoit S: Springer; New York, NY: pp. 397–420. 2005 | |
Benjamini Y and Hochberg Y: Controlling the false discovery rate: A practical and powerful approach to multiple testing. J Roy Statist Soc Ser B (Methodological). 57:289–300. 1995. | |
Huang da W, Sherman BT and Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 4:44–57. 2009. View Article : Google Scholar : PubMed/NCBI | |
Cowley MJ, Pinese M, Kassahn KS, et al: PINA v2.0: Mining interactome modules. Nucleic Acids Res. 40:(Database Issue). D862–D865. 2012. View Article : Google Scholar : PubMed/NCBI | |
Shannon P, Markiel A, Ozier O, et al: Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res. 13:2498–2504. 2003. View Article : Google Scholar : PubMed/NCBI | |
Jansen R, Greenbaum D and Gerstein M: Relating whole-genome expression data with protein-protein interactions. Genome Res. 12:37–46. 2002. View Article : Google Scholar : PubMed/NCBI | |
Kemmeren P, van Berkum NL, Vilo J, et al: Protein interaction verification and functional annotation by integrated analysis of genome-scale data. Mol Cell. 9:1133–1143. 2002. View Article : Google Scholar : PubMed/NCBI | |
Liu BH, Yu H, Tu K, Li C, Li YX and Li YY: DCGL: An R package for identifying differentially coexpressed genes and links from gene expression microarray data. Bioinformatics. 26:2637–2638. 2010. View Article : Google Scholar : PubMed/NCBI | |
Yokoyama C, Wang X, Briggs MR, et al: SREBP-1, a basic-helix-loop-helix-leucine zipper protein that controls transcription of the low density lipoprotein receptor gene. Cell. 75:187–197. 1993. View Article : Google Scholar : PubMed/NCBI | |
Porstmann T, Griffiths B, Chung YL, et al: PKB Akt induces transcription of enzymes involved in cholesterol and fatty acid biosynthesis via activation of SREBP. Oncogene. 24:6465–6481. 2005.PubMed/NCBI | |
Wu J, Liu J, Jia R and Song H: Nur77 inhibits androgen-induced bladder cancer growth. Cancer Invest. 31:654–660. 2013. View Article : Google Scholar : PubMed/NCBI | |
Degener S, Roth S, Mathers MJ and Ubrig B: Follow-up care-consequences of urinary diversion after bladder cancer. Urologe A. 53:253–262. 2014.(In German). View Article : Google Scholar : PubMed/NCBI | |
Lascu I: The nucleoside diphosphate kinases 1973–2000. J Bioenerg Biomembr. 32:211–214. 2000. View Article : Google Scholar | |
Rayner K, Chen YX, Hibbert B, et al: Discovery of NM23-H2 as an estrogen receptor β-associated protein: Role in estrogen-induced gene transcription and cell migration. J Steroid Biochem Mol Biol. 108:72–81. 2008. View Article : Google Scholar : PubMed/NCBI | |
Steeg PS, Bevilacqua G, Kopper L, et al: Evidence for a novel gene associated with low tumor metastatic potential. J Natl Cancer Inst. 80:200–204. 1988. View Article : Google Scholar : PubMed/NCBI | |
Yong G: Expression of C-erbB-2, EGFR and nm23-H1 in human bladder cancer and its clinical significance. Proc Clin Med. 2011((5)): 333–365. 2011. | |
Cook LM, Hurst DR and Welch DR: Metastasis suppressors and the tumor microenvironment. Semin Cancer Biol. 21:113–122. 2011. View Article : Google Scholar : PubMed/NCBI | |
Legin AA, Jakupec MA, Bokach NA, Tyan MR, Kukushkin VY and Keppler BK: Guanidine platinum (II) complexes: Synthesis, in vitro antitumor activity and DNA interactions. J Inorg Biochem. 133:33–39. 2014. View Article : Google Scholar : PubMed/NCBI | |
Chen S, Su L, Qiu J, et al: Mechanistic studies for the role of cellular nucleic-acid-binding protein (CNBP) in regulation of c-myc transcription. Biochim Biophys Acta. 1830:4769–4777. 2013. View Article : Google Scholar : PubMed/NCBI | |
Poli A, Ramazzotti G, Matteucci A, et al: A novel DAG-dependent mechanism links PKCα and Cyclin B1 regulating cell cycle progression. Oncotarget. 30:11526–11540. 2014. | |
Soria JC, Jang SJ, Khuri FR, et al: Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication. Cancer Res. 60:4000–4004. 2000.PubMed/NCBI | |
Nakamura N, Yamamoto H, Yao T, et al: Prognostic significance of expressions of cell-cycle regulatory proteins in gastrointestinal stromal tumor and the relevance of the risk grade. Hum Pathol. 36:828–837. 2005. View Article : Google Scholar : PubMed/NCBI | |
Yuan J, Krämer A, Matthess Y, et al: Stable gene silencing of cyclin B1 in tumor cells increases susceptibility to taxol and leads to growth arrest in vivo. Oncogene. 25:1753–1762. 2006. View Article : Google Scholar : PubMed/NCBI | |
Xu Y, Ayrapetov MK, Xu C, et al: Histone H2A.Z controls a critical chromatin remodeling step required for DNA double-strand break repair. Mol Cell. 48:723–733. 2012. View Article : Google Scholar : PubMed/NCBI | |
Meneghini MD, Wu M and Madhani HD: Conserved histone variant H2A.Z protects euchromatin from the ectopic spread of silent heterochromatin. Cell. 112:725–736. 2003. View Article : Google Scholar : PubMed/NCBI | |
Dong L, Bard AJ, Richards WG, Nitz MD, Theodorescu D, Bueno R and Gordon GJ: A gene expression ratio-based diagnostic test for bladder cancer. Adv Appl Bioinform Chem. 2:17–22. 2009.PubMed/NCBI |